Pharma Exclusives Pressreleases
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Wednesday, December 18, 2024Hansa Biopharma announced positive full results from the HMedIdeS single arm Phase study of imlifidase a first in class IgG cleaving enzyme in GuillainBarr Syndrome GBS and an indirect treatment comparison of the HMedIdeS study data to the Internati...
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution
Wednesday, December 18, 2024Roche announced today that it has received CE mark approval for its cobas Mass Spec solution including the cobas i analyser and the first Ionify reagent pack of four assays for steroid hormones The CE mark is the first milestone in the global launch...
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
Tuesday, December 17, 2024The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company Launched in the collaboration aims to deliver a sustainable supply of highquality affordable human and...
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Tuesday, December 17, 2024Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd and Sanofi today announce that the Phase b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis UC and Crohns disease CD RELIEVE UCCD investigated d...
Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
Friday, December 13, 2024Roche announced today that the European Medicines Agency has approved Vabysmo faricimab mg singledose prefilled syringe PFS for use in the treatment of neovascular or wet agerelated macular degeneration nAMD diabetic macular edema DME and macular ed...
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland
Wednesday, December 11, 2024Virax Biolabs Group Limited an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases today announced that it has entered into a nonexclusive distribution agreement with French company Tebubio to...
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
Wednesday, December 11, 2024Arvinas Inc and Pfizer Inc announced preliminary data from the ongoing Phase b portion of the TACTIVEU substudy of vepdegestrant in combination with abemaciclib among patients with locally advanced or metastatic estrogen receptor positive ERhuman epi...
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
Tuesday, December 10, 2024Roche announced today that new and updated data from its industryleading CDxCD Tcellengaging bispecific antibody programme were presented at the th American Society of Hematology ASH Annual Meeting Exposition December With more than bispecific an...
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Tuesday, December 10, 2024Artelo Biosciences Inc a clinicalstage pharmaceutical company focused on modulating lipidsignaling pathways to develop treatments for people living with cancer pain dermatologic and neurological conditions today announced the presentation of prelimin...
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
Monday, December 09, 2024Roche announced today data from a fiveyear followup of the pivotal phase III POLARIX study evaluating Polivy polatuzumab vedotin in combination with MabTheraRituxan rituximab cyclophosphamide doxorubicin and prednisone RCHP in people with untreated d...
